Impact of dominant stenoses on the serum level of the tumor marker CA19-9 in patients with primary sclerosing cholangitis

Zeitschrift fur Gastroenterologie

Volumn 43, Issue 6, 2005, Pages 587-590

  Petersen Benz, Christine ^a   Stiehl, A ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Bile duct carcinoma; Biliary obstruction; Endoscopic dilatation; Primary sclerosing cholangitis; Tumor marker CA19 9

Indexed keywords

ALKALINE PHOSPHATASE; CA 19-9 ANTIGEN; TUMOR MARKER; URSODEOXYCHOLIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILE DUCT; BILE DUCT CARCINOMA; CANCER RISK; COHORT ANALYSIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HEPATOBILIARY SYSTEM TUMOR; HUMAN; MAJOR CLINICAL STUDY; PRIMARY SCLEROSING CHOLANGITIS; STENOSIS; TREATMENT OUTCOME;

BILE DUCT NEOPLASMS; CA-19-9 ANTIGEN; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; COHORT STUDIES; CONSTRICTION, PATHOLOGIC; DILATATION; HUMANS; LONGITUDINAL STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URSODEOXYCHOLIC ACID;

EID: 21344444826     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-858105     Document Type: Article

References (13)

1. Bergquist A, Ekbom A, Olsson R et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36: 321-327
2. Broome U, Löfberg R, Veress B et al. Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential. Hepatology 1995; 22: 1404-1408
3. Miros M, Kerlin P, Harper J et al. Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis before transplantation. Gut 1991; 32: 1369-1373
4. Nashan B, Schlitt HJ, Tusch G et al. Biliary malignancies in primary sclerosing cholangitis: Timing for liver transplantation. Hepatology 1996; 23: 1105-1111
5. Rosen JB, Nagorney DM, Wiesner RH et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991; 213: 21-25
6. Goss JA, Shackleton CR, Farmer DG et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997; 225: 472-483
7. Chalsani N, Baluyut A, Ismail A et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study. Hepatology 2000; 31: 7-11
8. Hulterantz R, Olsson R, Danielsson A et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 1999; 30: 669-673
9. Collazos J, Genolla J, Ruibal A. CA19-9 in non-neoplastic liver disease. A clinical and laboratory study. Clin Chim Acta 1992; 210: 145-151
10. Stiehl A, Rudolph G, Klöters-Plachky P et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002; 36: 151-156
11. Katsanos KH, Kitsanou M, Christodoulou DK et al. High CA19-9 levels in benign biliary tract diseases. Report of four cases and review of the literature. Eur J Intern Med 2002; 13: 132-135
12. Pensioen CY, Vrouenraets SM, van Willigen de Witt AW et al. Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy 1999; 31: 305-309
13. Bergquist A, Tribukait B, Glaumann H et al. Can DNA cytometry be used for evaluation of malignancy and premalignancy in bile duct strictures in primary sclerosing cholangitis? J Hepatol 2000; 33: 873-877